Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 3 |
2019 | 1 |
2021 | 1 |
2022 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Page 1
Allbutt of Leeds and Duchenne de Boulogne: Newly discovered insights on Duchenne by a British neuropsychiatrist.
Rev Neurol (Paris). 2018 May;174(5):308-312. doi: 10.1016/j.neurol.2017.07.012. Epub 2018 Feb 1.
Rev Neurol (Paris). 2018.
PMID: 29358005
Review.
It is well-established that Guillaume-Benjamin-Amand Duchenne de Boulogne (1806-1875), and Jean-Martin Charcot (1825-1893) were the founding fathers of Parisian and French neurology during the second half of the 19th century, although much more is known about Charcot than …
It is well-established that Guillaume-Benjamin-Amand Duchenne de Boulogne (1806-1875), and Jean-Martin Charcot (1825-1893) were the f …
Mutational spectrum and phenotypic variability of Duchenne muscular dystrophy and related disorders in a Bangladeshi population.
Sarker S, Eshaque TB, Soorajkumar A, Nassir N, Zehra B, Kanta SI, Rahaman MA, Islam A, Akter S, Ali MK, Mim RA, Uddin KMF, Chowdhury MSJ, Shams N, Baqui MA, Lim ET, Akter H, Woodbury-Smith M, Uddin M.
Sarker S, et al.
Sci Rep. 2023 Dec 6;13(1):21547. doi: 10.1038/s41598-023-48982-w.
Sci Rep. 2023.
PMID: 38057384
Free PMC article.
Duchenne muscular dystrophy (DMD) is a severe rare neuromuscular disorder caused by mutations in the X-linked dystrophin gene. ...
Duchenne muscular dystrophy (DMD) is a severe rare neuromuscular disorder caused by mutations in the X-linked dystrophin gene. ...
Item in Clipboard
Dysferlin Exon 32 Skipping in Patient Cells.
Barthélémy F, Courrier S, Lévy N, Krahn M, Bartoli M.
Barthélémy F, et al.
Methods Mol Biol. 2018;1828:489-496. doi: 10.1007/978-1-4939-8651-4_31.
Methods Mol Biol. 2018.
PMID: 30171562
Item in Clipboard
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.
Phelip JM, Desrame J, Edeline J, Barbier E, Terrebonne E, Michel P, Perrier H, Dahan L, Bourgeois V, Akouz FK, Soularue E, Ly VL, Molin Y, Lecomte T, Ghiringhelli F, Coriat R, Louafi S, Neuzillet C, Manfredi S, Malka D; PRODIGE 38 AMEBICA Investigators/Collaborators.
Phelip JM, et al.
J Clin Oncol. 2022 Jan 20;40(3):262-271. doi: 10.1200/JCO.21.00679. Epub 2021 Oct 18.
J Clin Oncol. 2022.
PMID: 34662180
Clinical Trial.
Item in Clipboard
Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study.
Phelip JM, Edeline J, Blanc JF, Barbier E, Michel P, Bourgeois V, Neuzillet C, Malka D, Manfredi S, Desrame J; PRODIGE 38 Investigators.
Phelip JM, et al.
Dig Liver Dis. 2019 Feb;51(2):318-320. doi: 10.1016/j.dld.2018.11.018. Epub 2018 Nov 28.
Dig Liver Dis. 2019.
PMID: 30581069
Item in Clipboard
Cite
Cite